Building the Unbreakable Thicket: How to Defeat Generic Entry Without Relying on Your API Patent
The Problem With Betting Everything on One Patent Every pharmaceutical brand team eventually confronts the same uncomfortable math. The active […]
Beyond the Drug Patent Cliff: How Procurement Can Drive Immediate Savings with Generics and Biosimilars
The global biopharmaceutical industry is approaching a critical juncture as it faces a massive wave of patent expirations for some
The Patent is the Supply Chain: A Guide to Building Unbreakable Pharmaceutical Resilience
The Efficiency Trap: Why Lean Supply Chains Broke in 2024 The global pharmaceutical landscape is currently navigating a period of
How to Cut Pharmaceutical Costs Without Reducing Benefits
Why Most Cost-Cutting Advice Fails Employers and Plan Sponsors Every benefits consultant in America will tell you the same thing:
How to Cut Pharmaceutical Costs Without Reducing Benefits Read Post »
Cut Losses Early, Bet Big Late: The R&D Portfolio Decisions That Separate Pharma Winners from the Rest
Pfizer killed torcetrapib in 2006 after spending $800 million on a cholesterol drug that raised blood pressure instead of lowering
Understanding the Rise of Generic Drugs: A Strategic Imperative for the Modern Pharmaceutical Professional
The generic drug industry, often relegated to the background of high-profile blockbuster headlines and breakthrough therapy announcements, is not merely
Dropped Claims Don’t Lie
How Abandoned ANDA Litigation Patents Predict Weaker Enforcement The Most Underrated Signal in Generic Drug Intelligence When a brand pharmaceutical
Dropped Claims Don’t Lie Read Post »
Pharmaceutical Supply Chain Resilience: Lessons from the Pandemic
The pharmaceutical supply chain is a complex, multi-tiered network that historically has been optimized for efficiency and cost reduction above
Pharmaceutical Supply Chain Resilience: Lessons from the Pandemic Read Post »
The 1,825-day head start: How to stop a generic without a patent
Investors and executives often treat the expiration of a composition-of-matter patent as the singular moment of truth in a drug’s
The 1,825-day head start: How to stop a generic without a patent Read Post »
